Our CEO, Dr James Garner recently sat down with Morgans Senior Analyst Scott Power to provide a comprehensive update on our ongoing trials for our lead candidate, GDC-0084.
Professor Matt Dun was interviewed across leading broadcast and print media about his research into DIPG, a rare but aggressive form of childhood brain cancer.
Kazia Therapeutics is pleased to make its June 2019 newsletter available to investors.
Dr Matt Dun, a leading cancer researcher, discusses his research into Diffuse Intrinsic Pontine Glioma (DIPG) and GDC-0084.
Kazia Therapeutics Limited
Three International Towers
Level 24, 300 Barangaroo Avenue
Sydney NSW 2000, Australia
Which of the following group do you best fit?
Subscribe to our Email Alerts